A carregar...

Inhibition of Stress-Inducible Kinase Pathways by Tumorigenic Mutant p53

More than 50% of human cancers contain p53 gene mutations and as a result accumulate altered forms of the full-length p53 protein. Although certain tumor types expressing mutant p53 protein have a poor prognostic process, the precise role of mutant p53 protein in highly malignant tumor cells is not...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ohiro, Yoichi, Usheva, Anny, Kobayashi, Shinichiro, Duffy, Shannon L., Nantz, Regan, Gius, David, Horikoshi, Nobuo
Formato: Artigo
Idioma:en
Publicado em: American Society for Microbiology 2003
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC140653/
https://ncbi.nlm.nih.gov/pubmed/12482984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/MCB.23.1.322-334.2003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
Descrição
Resumo:More than 50% of human cancers contain p53 gene mutations and as a result accumulate altered forms of the full-length p53 protein. Although certain tumor types expressing mutant p53 protein have a poor prognostic process, the precise role of mutant p53 protein in highly malignant tumor cells is not well defined. Some p53 mutants, but not wild-type p53, are shown here to interact with Daxx, a Fas-binding protein that activates stress-inducible kinase pathways. Interaction of Daxx with p53 is highly dependent upon the specific mutation of p53. Tumorigenic mutants of p53 bind to Daxx and inhibit Daxx-dependent activation of the apoptosis signal-regulating kinase 1 stress-inducible kinases and Jun NH(2)-terminal kinase. Mutant p53 forms complexes with Daxx in cells, and consequently, mutant p53 is able to rescue cells from Daxx-dependent inhibition of proliferation. Thus, the accumulation of mutant p53 in tumor cells may contribute to tumorigenesis by inhibiting stress-inducible kinase pathways.